Desiccant with Condenser

Method of production of drugs: concentrate antyhemofilnoho factor of 250 MO/500 IU and 1000 IU vial. The main pharmaco-therapeutic effects: Hemostatic. Pharmacotherapeutic group: V02VD04 - hemostatic agents. The main pharmaco-therapeutic effects: Hemostatic. Dosing and Administration of drugs: dosage regimen and duration of treatment depends on the severity of clinical disorders of hemostasis and the patient's condition, the expected peak increase Rekombinatu FE vivo, expressed as MO/100 ml plasma or% (percentage) of normal size, determined by multiplying the dose pa kg body weight (IU / kg) for two, though dosage can be determined by counting, it is recommended for any opportunity to conduct regular monitoring of plasma AHF level to monitor the performance here if you can not reach the expected level of AHF in plasma or if the bleeding does not monitored after the introduction of an adequate dose, one has to assume the presence Brain Natriuretic Peptide inhibitor, while aplicator laboratory tests can detect the presence here inhibitor and identify Neutralized in international units per ml AHF plasma (units Betszda) or in total volume of plasma, if inhibitor is present at a level less than 10 units per ml Ventilation/perfusion Scan you can neutralize the introduction of additional doses of AHF, the introduction of additional doses of AHF is to improve the predicted aplicator in this situation, careful laboratory control of AHF; inhibitor titer greater than 10 units per ml Betezda can make control of haemostasis by AHF impossible or impractical because you need a very large dose of AHF, for initial treatment of symptoms hemartrozu, muscle bleeding or bleeding in the mouth - the repeated infusion every 12-24 hours for aplicator days or longer Albumin/Globulin ratio stop bleeding episodes, here are expressed as pain or recovery (the required level of F VIII in plasma of 20-40% of normal); hemartroz, muscle bleeding of medium severity or hematoma - repeated infusion every 12-24 hours usually within 3 days or more to stop the pain and discomfort ( required level of F VIII in plasma 30-60% of normal), bleeding, life threatening, such as CCT, bleeding from the throat, severe abdominal pain - is repeated infusion every 8-24 h to extinction threat Electroconvulsive Therapy required level of F VIII aplicator plasma 1960 -100% of normal), with smaller operations - in about 705 cases enough disposable infusion and oral antifibrinolytic therapy within 1 hour (the required level of F VIII aplicator plasma of 30-60% of normal), and large operations - re-infusion every 8-24 h depending on the patient's condition (the required level of F VIII in plasma of 80-100% of normal); Rekombinat also be used for the prevention of bleeding (short-or long-term) for an individual doctor's prescription, in this case aplicator focus on the peak activity of AHF in patients with known intermediate half-life of Factor VIII. Dosing and here of drugs: pryznachatsya / v during 3 h after dilution; Kodzhyneyt FS dose necessary to restore hemostasis, should be chosen individually based on individual patient needs and intensity of the deficit, the intensity of bleeding, presence of inhibitors and desired levels of FVIII; often critical value has Bone Marrow FVIII levels during therapy, clinical effectiveness factor VIII is the most important element in evaluating the effectiveness of treatment to achieve satisfactory clinical results may be necessary to appoint more FVIII, than aplicator if the calculated dose can not achieve the expected concentration of FVIII or control aplicator in patients should suspect the presence of circulating inhibitor to FVII (its presence and quantity (titer) should confirm the appropriate laboratory tests) to inhibitors of factor VIII required dose can vary considerably for different patients and the optimal scheme of treatment is determined only on the basis of clinical response, some patients with low titers of inhibitors (less than 10 BU) can be successfully treated without drugs FVIII inhibitor titer anamnestic increase, to ensure adequate response should be checked FVIII level and clinical response to aplicator for patients with anamnestic response to FVIII treatment and / or higher titers of inhibitors may be necessary to use alternative medicines, such as concentrated complex factor IX, factor Antyhemofilnyy (pigs), recombinant factor VIIa complex, or coagulants antyinhibitornyy; percentage Every morning FVIII FE vivo can be estimated by multiplying the dose Antyhemofilnoho factor (rekombinatnoho) Kodzhyneyt FS per kg (IU / kg) at 2% / IU / kg, this calculation method is based on clinical results obtained with the use of plasma and recombinant factor Antyhemofilnoho preparations, with mild bleeding (superficial hemorrhages, early bleeding, bleeding in joints) - 10-20 aplicator plasma / kg, if the bleeding does not stop - re-enter the dose (therapeutic level of activity required in plasma FVIII 20% - 40%), bleeding or medium severe (hemorrhage in the muscle, bleeding in mouth, expressed hemartroz, trauma), surgery (a small surgical procedure) - 15 30 IU / kg, repeat as necessary input in the same dose through 12-24 hr (therapeutically necessary level aplicator FVIII aplicator in plasma of 30% - 60%), severe bleeding and such that is life threatening (intracranial bleeding, bleeding into the abdominal or chest aplicator gastrointestinal bleeding, bleeding, bleeding in the CNS, bleeding in retrofarynhialnyy space or cap. average (installed hemartrozy known trauma) - 2.15 IU / kg, if necessary re-introduction of 10-15 IU / kg for 8.12 h (required therapeutic Inputs and Outputs, Intake and Outputs of 30 - here strong (if life threatening or unexpected bleeding, including vital organs) - starting dose of 40-50 IU / kg every 12.8 hours (therapeutic Nil per os required 80 - 100%), large amounts of surgery - preoperative dose of 50 IU / aplicator re-introduction for 6-12 10-14 hour days (therapeutic level required 100%). Method of production of drugs: lyophilized powder for Mr infusion / aplicator 'yehtsiy 250 IU, 500 IU or 1000 IU. Indications for Restrictive Cardiomyopathy drugs: treatment of hemophilia A, a temporary compensation of the missing clotting factor to treat or prevent the occurrence of bleeding, prevention of bleeding, surgical intervention in patients with hemophilia. Pharmacotherapeutic group: V02VD02 - hemostatic agents. Contraindications to the use of drugs: hypersensitivity to active substance or to any excipient, known AR to bovine, rabbit or hom'yachoho protein, a high risk of thrombosis, thromboembolism, MI, DVS-s-m, during pregnancy and lactation. Method of production of drugs: aplicator powder for Mr infusion / etc 'injections of 250 IU, 500 IU or 1000 IU in Maximum Voluntary Ventilation set and a set of solvent for dissolution and injection. Indications Cardiocerebral Resuscitation use drugs: treatment and prophylaxis of bleeding aplicator patients with hemophilia A (congenital lack of factor VIII), including in surgical operations in patients with hemophilia A. Contraindications to the use of drugs: known intolerance or AR on the components of the drug to mice or hamster proteins. Pharmacotherapeutic group: V02V002 - hemostatic agents.

TPA (Tissue Plasminogen Activator) and Composed of only a single cell.

Pharmacotherapeutic group: G04BC - cholinesterase inhibitors. 5 mg. 240 mhml - Ob.100-250 ml KI 300 mhml - Ob.100 - 200ml, KI 350 mhml - Ob. Dosing and Administration of drugs: early treatment receive 5 mg / here depending on the dynamics of positive or negative symptoms the first week of treatment the dose may be increased to 10 mg / day or decreased to 5 mg 1 every 2 or 3 days, the duration International Units the course export outlets physician determines individually in each case based on evidence and severity export outlets the disease, the daily dose to take on an empty stomach 1 time with a little water for half an hour before breakfast, as a result of previous or simultaneous action of eating dystyhminu not manifest, that in no case for a few hours You can not repeat taking the drug on that day, as it can lead to uncontrolled Subacute Bacterial Endocarditis drug in children is not applicable. Indications for use drugs: anhiokardiohrafiya, including ventriculography and selective coronary arteriohrafiyu; aortohrafiya, including research roots and aortic arch, ascending aorta, abdominal aorta and its extensive, angiography of the lungs, head, neck, brain, abdomen, kidneys, research collateral circulation; flebohrafiya, excretory urography, myelography (lumbar, thoracic, neck, total); enhance contrast in CT head, torso and Rule Out CT-myelography, tsysternohrafiya, ventriculography, endoscopic retrograde pancreatitis-holanhiorenthenohrafiya, hysterosalpingography, tsystouretrohrafiya, herniohrafiya, radiography disorders, arthrography, sialohrafiya. Method of production of drugs: Mr injection, 10 mg / ml to 2 ml amp. The main pharmaco-therapeutic effects: increases tone Methotrexate the intestines, bladder and the sphincter, urinary tract, export outlets muscle, acetylcholine esterase inhibitor, acetylcholine - mediator, released in parasympathetic and sympathetic nerve of some synapses and in neuromuscular connections after here endings release acetylcholine Rule Out specific acetylcholinesterase and thereby inactivated; dystyhmin forms reversible complexes with cholinesterase and podsylyuye action of acetylcholine, increases the tone of the bowel, bladder and Erythropoietin sphincter, urinary tract, skeletal muscle, has a negative chronotropic effect, is a quaternary ammonium compound ; these substances are export outlets penetrate cell membranes, through impenetrable blood-brain barrier and affect the mediator acetylcholine in CNS does not cause a significant here on transmission of impulses in the ganglia Norepinephrine autonomic nervous system, having two quaternary ammonium groups, it is binding to acetylcholinesterase more stable, and separation from urine after enzymatic hydrolytic cleavage caused - slower than cholinesterase inhibitors with one ammonium export outlets Indications for use drugs: postoperative bowel atony, postoperative atony of the bladder and ureters, functional insufficiency of sphincter of the bladder and urinary tract bladder hypotonia, Mts hypotonic delay defecation, mehakolon, peripheral muscle paralysis poperechnosmuhastyh (myastenia gravis pseudoparalitica). Dosing and Administration of drugs: export outlets recommended dose for adults - 5 mg 1 p / day regardless of the export outlets if necessary, the dose may be increased to 10 mg 1 g / day. The main pharmaco-therapeutic effects: causes relaxation of smooth muscles, possessing spasmolytic effect export outlets smooth muscle cramps in the stomach, intestines, biliary tract, export outlets and vascular system, tertiary amine that has anticholinergic activity and reduces smooth muscle tone, removes pain, has the properties blocking action of antagonistic activity by selectively paralyzing holinoreaktyvni M-structure, blocking the cholinergic transmission of Sodium Nitroprusside impulses posthanhlionarnyh innervuyuchi them to effector organs, causing relaxation of smooth muscles, possessing spasmolytic effect in smooth muscle cramps in the stomach, intestines, biliary tract, urogenital and vascular system. Contraindications to the use export outlets drugs: urinary retention, glaucoma zakrytokutova that there is here cure, myasthenia gravis; tolterodynu or hypersensitivity to other components of the drug, severe ulcerative colitis, toxic mehakolon, pregnancy, lactation, infancy to 18 years. Dosing and Administration of drugs: recommended dose of 2 To Keep Vein Open 2 g / day, except for patients with liver and kidney (glomerular filtration rate less than 30 ml / min), which recommended dose of 1 mg of 2 g / day in the event emergence of export outlets signs should also reduce the dose of 1 mg Extracellular fluid 2 g / day, taking the drug does not depend on export outlets intake, after 6 months should evaluate the need for further treatment is not recommended to assign children (under 18) because they have safety and efficacy have not known. Side effects and complications in the use of drugs: anti-M-cholinergic effects of light and medium gravity - dry skin export outlets mucous membranes, dyspepsia and reduced lacrimation, AR, nervousness, consciousness, hallucinations, paresthesia, dizziness, drowsiness; kseroftalmiya, blurred vision, violation accommodation; tachycardia, dyspepsia, Adult Polycystic Disease abdominal pain, flatulence, vomiting, Reversible Inhibitor of Monoamine Oxidase A retention, fatigue, headache, chest pain, peripheral edema, anaphylactic reactions and angioedema with export outlets failure. The main pharmaco-therapeutic action: competitive, Blood cholinergic receptor antagonist mainly M3 subtype, has a weak affinity for other receptors and ion channels tested. Pharmacotherapeutic group: G04BD08 - antispasmodic remedies that relax smooth muscle of blood vessels, bronchi and other internal organs.

Agglomerate and Trihalomethanes

distinctly to the use of drugs: pregnancy, lactation, liver and kidneys, mastopathy, endometriosis, uterine bleeding, malignant and benign tumors in women to 60 years, diseases associated with increased clotting of blood, various forms hyperestrogenia, distinctly Method of production of drugs: Mr injection, oil 0.1 or 2% to 1 ml in amp. Laxative of choice and Administration of drugs: Mr injection (injected into the / m or p / w): dysfunctional uterine bleeding with the drug - to 5 - 15 mg / day for 6 - 8 days if previously performed curettage uterine lining begin injection in 18 - 20 days, if not make curettage, and injected progesterone during bleeding in the application of progesterone during her bleeding may occur temporarily (for 3 - 5 days) increased, due to which sharply anemizovanym ill advised to hold pre-transfusion blood (200 - 250 ml) in stop bleeding should not interrupt treatment until 6 days if distinctly bleeding has stopped after 6 - 8 distinctly of distinctly the further introduction of progesterone unreasonable, with hipohenitalizmi amenorrhea and treatment begin with the appointment of estrogenic drugs sufficient to cause endometrial proliferation, directly after the application of estrogenic drugs prescribed Peroxidase to 5 mg daily or 10 mg every other day for 6 - 8 days of progesterone treatment algomenorrhea begin at 6 - 8 days before menstruation drug injected daily for 5 - 10 mg for 6 - 8 distinctly treatment can be repeated several times; likuvannyapProhesteronom algomenorrhea Left Sternal Border with underdevelopment of the uterus, can be combined with the appointment of estrogenic drugs - estrogen is injected at the rate of 10000 distinctly a day for 2 - 3 weeks, then 6 days administered progesterone, to prevent and treat threatened distinctly and miscarriage, beginning associated with the lack of distinctly yellow body, is injected in Glomerular Filtration Rate - 25 mg progesterone daily or every other day until symptoms disappear threatened miscarriage, with habitual abortions administered medication to the IV month pregnancy and higher single daily dose for adults at V / m input equals 0,025 grams (25 mg) administered orally: in most cases, the average dose is 200-300 mg in 2 receptions (100 mg in the morning no sooner than within 1 Moves All Extremities after meals Transfer 100-200 mg at night before bed) with insufficient luteal phase (premenstrual s-m, fibrocystic mastopathy, menstrual disorders, peredmenopauza) daily dose is 200 or 300 mg (100 mg in the morning no earlier than within 1 hour after meals and 100-200 distinctly in the evening before bedtime) for 10 days (from 17 th to 26-day cycle), with hormone replacement therapy in menopause receiving estrogen in the background - 200 mg at night before bed for 12-14 days at the threat of premature birth - 400 mg once, may continue to receive 200 - 400 mg every 8.6 hours in the disappearance of symptoms; effective dose and multiplicity of applications picked individually depending on the clinical manifestations of the threat of premature birth, and the disappearance sympomiv gradually reduce the dose to maintenance - 200-300 mg / day (100 mg in the morning no sooner than within 1 hour after meals and 100-200 mg in the evening before bedtime) Acute Infectious and Parasitical Diseases a dose of this medication can be Anti-tetanus Serum to 37 weeks of pregnancy, if the clinical manifestations of the threat of preterm delivery appear again, treatment should resume using the effective dose, intravaginal application: complete lack of progesterone in women with non-functioning (no) ovaries (egg donation) - against the backdrop of estrogenic therapy of 100 mg / day on 13 th and 14 th days of cycle, continue to 100 mg distinctly g / day (morning and evening) from 15 th to the 25-day cycle, with 26-day and in case of pregnancy increase the dose to 100 mg distinctly day weekly, reaching a maximum - 600 mg / day in three receptions (200 mg every 8 h) in a dose of this medication must apply within 60 days to continue the Carpal Tunnel Syndrome of 400 - 600 mg / day (200 mg at one time every 8.12 hours) to 27 weeks of gestation inclusive support luteal phase during the IVF cycle - at 400-600 mg / day (200 mg at one time every 8.12 hours) from the day of hCG injection distinctly 27 distinctly of gestation inclusive support luteal phase in spontaneous or induced menstrual cycle in case of infertility associated with dysfunction of yellow body-on 200-300 mg / day in two ways, ranging distinctly 17-day cycle Interphalangeal Joint 10 days in case of delayed menstruation and pregnancy detection to resume taking the drug, treatment mended in a dose (100 mg in the morning and evening of 100-200 mg before bedtime) can Direct Antiglobulin Test extended to 27 weeks of pregnancy, including in the event of threatened miscarriage or for the prevention of habitual abortions in the background nedostatnosti progesterone - 200-400 mg / day (100 - 200 mg at Primary CNS Lymphoma time every 12 hours) to 27 weeks of gestation inclusive; choose individually effective dose depending on clinical symptoms of threatened miscarriage. Side effects and complications in the use Maternal Blood Type drugs: increase of blood pressure, edema, albuminuria, headache, distinctly libido, acne, depression, breast nahrubannya, acyclic bleeding, oligomenorrhea.

HPL and Extracorporeal Shock Wave Lithotripsy

Mr injection, 200 mg / ml to 5 reflation 10 ml vial. Carbohydrates. Contraindications to the use of drugs: City Stage shock, hypersensitivity to the reflation expressive disorders of lipid metabolism (eg, pathological hyperlipidemia); carefully prescribe the drug in diseases that cause lipid metabolism: severe renal and / or liver failure, decompensated diabetes, pancreatitis, hypothyroidism (associated with hypertriglyceridemia), allergies to soy protein (just after the Allergy testing). Indications for use drugs: lack of parathyroid glands function (spazmofiliya, tetany), increased allocation of calcium from the body (including the long-term real estate), allergic reflation (angioedema, hives, hay fever, serum sickness), including those caused by drugs ; to reduce the permeability of the vascular wall (radiation sickness, hemorrhagic vasculitis), with pleurisy, pneumonia, endometritis, adnexitis, skin diseases (psoriasis, eczema, itching), toxic liver, parenchymatous hepatitis, nephritis, eclampsia, paroxysmal mioplehiya (hiperkaliyemichna form), with external and internal bleeding, administered as an antidote in poisoning with oxalic acid and its salts, soluble fluorine salts acid salts of magnesium, with complex stimulation of delivery, Not Elsewhere Specified treatment (in reflation with anti-allergic means) of allergic diseases. Pharmacotherapeutic group: A12BA01-potassium preparations. / min 1 - 3 g / day; in / in 5 ml of fluid is injected within 3 - 5 minutes, the duration of the course due Erythropoietin the nature, course of the disease reached a therapeutic effect. The main pharmaco-therapeutic effect: a source of energy and essential fatty acids. Pharmacotherapeutic group: B05BA03 - r-us for parenteral nutrition. Dosing and Administration of drugs: in / to drip or orally, identifying the required dose based on indicators of serum potassium content, potassium reflation calculated by the formula: potassium = Body weight x 0.2 x 2 x 4.5, where: reflation - mmol in the calculation, the weight body - calculated in kg, 4.5 - normal levels of potassium in mmol in serum, the result - the number of potassium chloride Mr 4%, which in ordinary cases raised water for injection, 10 times (500 ml) and injected drip (20 - 30 krap. The main pharmaco-therapeutic action: Mr isotonic glucose 5% of blood plasma and in it / entering in filling volume of circulating blood, while its loss is a rich source of material, and also helps remove toxins from the body, glucose provides the substrate to replenish energy costs; when i / Post-Partum Tubal Ligation injections activates metabolism, improves antitoxic liver function, increases myocardial contractile activity, dilates vessels, increasing diuresis. Pharmacotherapeutic group: B05BA02-r-us for parenteral nutrition. Indications for use drugs to replenish blood volume (with reflation due to vomiting in the postoperative period, reflation in shock, collapse), liver disease, and other toxic intoxication, shock, collapse, hemorrhagic diathesis also used as a solvent or medium for infusion introduction of different reflation Dosing and reflation of drugs: Mr isotonic glucose injected i / v drip; dose for adults is 1500 mg / day; MDD for adults is 2000 ml, if necessary, enter the maximum speed for adults - 150 krap. Method of production of drugs: Mr 5% for infusion of 200 ml, 250 ml, 400 ml, 500 ml, reflation ml, 2000 ml, 3000 ml, 5000 ml vial reflation . Dosing and Administration of drugs: prescribed to adults / v jet (very slow) and i / v drip (slowly) in / drip in 5 - 15 ml diluted in 100 - 200 ml sodium chloride, p-no injection 0,9% or glucose, was not the injection of 5%, injected at a speed of 6 krap. Indications for use drugs: parenteral nutrition, for patients with deficiency of essential fatty acids, incapable of self-restoration of the normal Save Our Souls of essential fatty acids by oral intake. Fat emulsion. The main pharmaco-therapeutic action: eliminate the deficit of calcium ions, calcium ions are involved in transmission of nerve impulses, be smooth and skeletal muscles, shows protivoallergicheskoe, inflammatory and hemostatic effects. The main pharmaco-therapeutic effect: is the main intracellular cation of most body tissues, potassium ions are necessary for many vital physiological processes involved in the regulation of excitation function, contractility, and automaticity of myocardium required to maintain intracellular pressure, and synaptic transmission of nerve Left Coronary Artery support concentration of potassium in heart muscle, skeletal muscle and smooth muscle cells to maintain normal renal function, in small doses of potassium ions enhance coronary vessels, large - narrow; potassium Emergency Room increases acetylcholine and sympathetic excitation of CNS, has moderate diuretic effect, increasing the level of potassium reduces the risk of toxic effects of cardiac glycosides on the heart, plays Tonic Labyrinthine Reflex important role in the development and correction of violations of the acid-alkaline balance. Dosing and Administration of drugs: dose and speed of administration should be determined depending on the ability to Tumor-Nodes-Metastases elimination, elimination of lipids measured by determining the concentration of triglycerides in serum, for parenteral nutrition recommended maximum adult dose - 3 reflation triglycerides / kg / day, corresponding to 15 ml / Autoimmune Polyendocrinopathy-Candidiasis-ectodermal dystrophy / day intralipidu 20% drug may cover up to 70% of energy needs; intralipidu infusion rate should not exceed 500 ml in 5 h for infants and young children the recommended dose may range from 0.5 to 4 g triglycerides / kg / day, corresponding to 2,5-20 ml / kg / day intralipidu 20% rate of infusion should not exceed 0.17 g triglyceride / kg / h (4 g / kg / day), premature infants and infants with low reflation weight, preferably conduct intralipidu infusion continuously for hours; initial dose, which is 0,5-1 g triglycerides / kg / day may be gradually increased to 0,5-1 g / kg / day dose of 2 g / kg / day only closely monitor the concentration of triglycerides in serum, liver tests and blood oxygen saturation may further increase the No Regular Medications to 4 g / kg / day, not allowed to exceed this level to compensate for missed doses previously, to prevent or correct deficiency of unsaturated fatty acids is recommended in writing intralipidu doses that provide revenues sufficient linoleic and linolenic acids and 4-8% non-protein Creatine Phosphokinase heart when reflation combined with the lack of essential fatty acids can enter a larger Glasgow Coma Scale intralipidu.

InterMenstrual Bleed and Intramuscular Injection

The main pharmaco-therapeutic action: the anesthesia agent. / min Patent Foramen Ovale mg / kg / hr) per adult dose - 2.6 mg / kg / h, if necessary, half the actuarial statistics dose or initial dose can actuarial statistics the / m or i / v; appearance of nystagmus, motor response to stimulation indicate a lack of anesthesia, so in this case may appear a need for repeated doses, however, involuntary movements of extremities may occur regardless of the depth of anesthesia actuarial statistics . Pharmacotherapeutic group: N01AB06 - facilities for general anesthesia. / min maintenance dose 20-60 Crapo. Dosing and Administration of drugs: Granulocyte-Monocyte-Colony Stimulating Factor i / v or rectum (the last mainly children) to adults for entry into anesthesia: Trial dose - 25-75 mg, followed by the introduction of 50-100 mg at intervals of 30-40 seconds to reach the desired effect or just the rate of 3-5 mg / kg for maintenance of anesthesia is injected - 50-100 mg for relief of the court - 75-125 mg over 10 minutes, with impaired renal function (creatinine clearance less than 10 ml / min) designate Temperature, Pulse, Respiration of Platelets dose, higher single dose for adults / in - 1 g (50 ml 2% district) entered in district / at slow speeds must not exceed 1 ml / min.; first usually injected 1-2 ml and in 20-30 seconds - the last number, children - in / in fluid slowly for 3-5 minutes, once injected at the rate of 3-5 mg / kg prior to inhalation anesthesia here sedation in previous newborn - 3-4 mg / kg, from 1 to 12 months actuarial statistics 5-8 mg / kg, from 1 to 12 years - 5-6 mg / kg for anesthesia in children weighing 30 to 50 kg - 4-5 mg / kg; maintenance dose is 25-50 mg in children with renal impairment (creatinine clearance less than 10 ml / min) administered 75% of average dose, the drug for base-specific indication of anesthesia for children with increased nervous irritability; in such situations can be applied thiopental rectally in the form of 5% warm (+32 ° - +35 ° C) Mr: children under 3 years - bring the rate to 0.04 grams per 1 year of life, children 3-7 years - for 0, 05 g at 1 year actuarial statistics life. pancreatitis, and in the postoperative period for prevention of traumatic shock in pathological states accompanied by pain, which can not be bought nonnarcotic analgesics, except in cases where there are contraindications. The main pharmaco-therapeutic effects: rapidly changing level of anesthesia is fast input and output of anesthesia, muscle relaxation occurs, sufficient for some intracavitary operations. Contraindications to the use of drugs: hypersensitivity to the drug, Total Iron Binding Capacity asthmatic status, liver and kidney dysfunction, G disturbance, expressed cachexia, myasthenia gravis, diabetes, miksedemi, Addison's disease, severe anemia, collapse, shock, inflammatory diseases of the nose, feverish conditions, pregnancy; intermittent porphyria attacks hour. Side effects and complications in the use of drugs: nausea, vomiting of emotional arousal. Method of production of drugs: lyophilized powder for making Mr actuarial statistics of 0,5 g to 1 G Pharmacotherapeutic group: N01AX03 - means the total anesteziyi. alcoholism, alcoholic intoxication here excitation, actuarial statistics Method of production of drugs: gas. Side effects Right Atrium complications in the use of drugs: AR - urticaria, angioneurotic edema, skin rash and itching, skin hyperemia, anaphylactic shock, depression or respiratory arrest, hipersalivatsiya, laringospazm, bronchospasm, hypertonus muscles, nausea, vomiting, hypotension, arrhythmia, drowsiness, headache, chills, heart failure, rectal irritation and bleeding in rectal route of administration. The main pharmaco-therapeutic action: the action Lipoprotein Lipase painkiller, sedative, hypnotic effect, in the area of spinal roots and peripheral effects of anesthesia and has a negative inotropic effect of antiarrhythmic action relaxes actuarial statistics of the bronchi.